India, Aug. 23 -- Routine testing for a specific 'lipoprotein' known as Lp(a) would be a cost saving way to significantly reduce the risk of cardiovascular disease and save lives according to an international taskforce led by Monash University.
Elevated levels of Lp(a) impacts an estimated one in five people worldwide and leads to an increased risk of cardiovascular disease, the number one cause of death globally. Despite this, levels of Lp(a) are not routinely measured in clinical practice and most people with elevated levels don't know they're at risk - something the researchers call a "public health blindspot."
The Lp(a) International Taskforce was established by the FH Europe Foundation. Published in Atherosclerosis, the study analyse...